Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Issues a Buy Rating on Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
SpringWorks Therapeutics Analyst Ratings
SpringWorks Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating
Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline
Springworks Therapeutics (SWTX) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
SpringWorks Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
Springworks Therapeutics: A Buy Rating on Ogsiveo's Success and Promising Pipeline
SpringWorks Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Goldman Sachs Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Analyst Ratings